Novavax's partner Genocea announces positive data from Phase I/IIA HSV-2 trial
Sep 20, 2013 (MarketLine via COMTEX) --
Novavax, Inc., a clinical-stage biopharmaceutical company, has reported that its partner, Genocea Biosciences Inc., a vaccine discovery and development company, has announced positive interim data from a Phase I/IIA clinical trial of its lead candidate, GEN-003, a first-in-class investigational protein subunit vaccine for patients with moderate-to-severe herpes simplex virus type 2, or HSV-2, infection.
Genocea's herpes simplex virus-2 therapeutic vaccine candidate uses the Novavax proprietary adjuvant known as Matrix-M.
Genocea's results showed that vaccination with GEN-003 potentiated by the Matrix-M adjuvant can significantly blunt HSV-2 infection and reduce viral shedding. The two highest dose cohorts, both adjuvanted with Matrix-M, demonstrated significant reductions in viral shedding (51% and 30%, respectively, each p<0.001). No serious adverse events were related to the vaccine.
The partnership agreement with Genocea covers the use of Matrix-M in the development of vaccines against specific diseases including herpes simplex virus type 2.
"The strong showing of Genocea's vaccine candidate, which includes our proprietary adjuvant Matrix-M, underscores the potential of the adjuvant to Novavax, and the value of our recent acquisition of Isconova," said Stan Erck, President and CEO of Novavax.
"The early clinical response to GEN-003 in this trial is unprecedented in HSV-2. We are proud to be pioneers in the field of T cell-directed vaccines," noted Chip Clark, President and CEO of Genocea.
Matrix-M is a patented vaccine adjuvant being developed and produced by Novavax. Adjuvants enhance the efficacy of a vaccine while maintaining safety; they increase the vaccine's ability to produce antibodies and induce a cellular response that is important for modern vaccines.
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
[ InfoTech Spotlight's Homepage ]